Shantani Gets Investment from IIF and Blume Ventures


Bangalore: Pune based Shantani Proteome Analytics; a chemical proteomics technology platform has procured investment from Blume Ventures and India Innovation Fund. This investment has its focus more emphasized on supporting innovation driven startups in technology and life sciences with its early stage funding as reported by Dealcurry.com

Shantani was founded by a management team with global scientific and business expertise. It focuses more on the development of advanced technology applications for the use by drug discovery organizations for drug test discovery. Its chemical proteomics technology platform is used to identify and validate a few but rightful targets of drugs and drug like bioactive molecules in a very short span of time allowing a great saving in the cost, for about 50-70%.

This platform is also used for drug repositioning purposes and to identify off target interactions of a drug to understand its toxicity profile. Dr.Chaitanya Saxena, Chief Executive Officer and Board of Director, Shantani Proteome Analytics Pvt. Ltd says “"We have an innovative and exciting technology in the niche area of drug (target) discovery. However to grow our business we were not only looking for capital but the right partners with the understanding of technology driven businesses and a strong network in life sciences to help take our start-up to next stage. IIF led funding came with all those ingredients."

IIF had also invested 10 crores in digital media Technology Company ‘Sure Waves Media Tech’, in the year 2011. Blume ventures had also invested in a Bangalore based startup called HashCube recently. Rajesh Rai the CEO of IIF said "We are excited to partner with Dr.Saxena and the Shantani team. Shantani has developed a unique technology platform with significant benefits for drug design and development. We look forward to supporting the company through the IIF network", as reported by Indiaprwire.